GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
Portfolio Pulse from
GRAIL and Quest Diagnostics have partnered to offer GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test through Quest Diagnostics' test ordering system. This collaboration aims to streamline the process for physicians and patients in the U.S.
February 12, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics has partnered with GRAIL to offer the Galleri® MCED Test through its system, enhancing its service offerings in cancer detection.
By integrating GRAIL's Galleri® test into its system, Quest Diagnostics can enhance its service offerings, potentially attracting more healthcare providers and patients, which could positively impact its business.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
GRAIL has partnered with Quest Diagnostics to offer its Galleri® MCED Test through Quest's system, potentially increasing test accessibility and adoption.
The partnership with Quest Diagnostics allows GRAIL to leverage Quest's extensive network, potentially increasing the adoption of the Galleri® test. This could lead to higher revenues and market presence for GRAIL.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80